FDA brief shows CV risk with etoricoxib. Part 4

The briefing writing for lumiracoxib is much shorter (3 pages, compared with 55 for etoricoxib).
It focuses on results from the ongoing GOAL
written report in 18 000 patients with osteoarthritis, in which
lumiracoxib was compared with etoricoxib and ibuprofen.
This rumination “definitively” showed a GI plus for lumiracoxib over
both NSAIDs in patients not taking aspirin and showed a smaller plus
(almost none for ibuprofen) for those taking aspirin, writes FDA
commentatorDr Calophyllum longifolium Lourdes Villalba.

The appraisal of cardiovascular preventative considered Anti-Platelet Trialist Collaborationism
(APTC) end points, which include a whole of confirmed and probable
cardiac deaths as well as fatal and nonfatal myocardial infarctions and
strokes.
In the constituent of the drawing that compared lumiracoxib with
ibuprofen, the numeral of these events (including the whole figure of
myocardial infarctions) is similar.
However, in the examination with naproxen, there were more events in
the lumiracoxib chemical group, and this dispute was driven by nonfatal
myocardial infarctions in the nonaspirin-user grouping.
These findings are consistent with the findings for rofecoxib as
compared with naproxen in the ZIP field of study, the referee notes.
This is a part of article FDA brief shows CV risk with etoricoxib. Part 4 Taken from "Generic Arcoxia (Etoricoxib)" Information Blog